NM_003001.5:c.397C>T

Variant summary

Our verdict is Likely pathogenic. The variant received 8 ACMG points: 12P and 4B. PVS1_StrongPP5_Very_StrongBS2

The NM_003001.5(SDHC):​c.397C>T​(p.Arg133*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000248 in 1,613,832 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. R133R) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.0000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000027 ( 0 hom. )

Consequence

SDHC
NM_003001.5 stop_gained

Scores

3
2
2

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:17

Conservation

PhyloP100: 1.64

Publications

32 publications found
Variant links:
Genes affected
SDHC (HGNC:10682): (succinate dehydrogenase complex subunit C) This gene encodes one of four nuclear-encoded subunits that comprise succinate dehydrogenase, also known as mitochondrial complex II, a key enzyme complex of the tricarboxylic acid cycle and aerobic respiratory chains of mitochondria. The encoded protein is one of two integral membrane proteins that anchor other subunits of the complex, which form the catalytic core, to the inner mitochondrial membrane. There are several related pseudogenes for this gene on different chromosomes. Mutations in this gene have been associated with paragangliomas. Alternatively spliced transcript variants have been described. [provided by RefSeq, May 2013]
SDHC Gene-Disease associations (from GenCC):
  • hereditary pheochromocytoma-paraganglioma
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
  • pheochromocytoma/paraganglioma syndrome 3
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • Carney-Stratakis syndrome
    Inheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Genomics England PanelApp
  • gastrointestinal stromal tumor
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp
  • renal cell carcinoma
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • Cowden disease
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • mitochondrial disease
    Inheritance: Unknown Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_pathogenic. The variant received 8 ACMG points.

PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most 50 bp of the penultimate exon, not predicted to undergo nonsense mediated mRNA decay. There are 7 pathogenic variants in the truncated region.
PP5
Variant 1-161356832-C-T is Pathogenic according to our data. Variant chr1-161356832-C-T is described in ClinVar as Pathogenic. ClinVar VariationId is 183753.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS2
High AC in GnomAdExome4 at 39 Unknown,AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SDHCNM_003001.5 linkc.397C>T p.Arg133* stop_gained Exon 5 of 6 ENST00000367975.7 NP_002992.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SDHCENST00000367975.7 linkc.397C>T p.Arg133* stop_gained Exon 5 of 6 1 NM_003001.5 ENSP00000356953.3

Frequencies

GnomAD3 genomes
AF:
0.00000658
AC:
1
AN:
152062
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000147
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000361
AC:
9
AN:
249038
AF XY:
0.0000297
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000539
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000267
AC:
39
AN:
1461770
Hom.:
0
Cov.:
32
AF XY:
0.0000234
AC XY:
17
AN XY:
727192
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33480
American (AMR)
AF:
0.00
AC:
0
AN:
44722
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26134
East Asian (EAS)
AF:
0.0000252
AC:
1
AN:
39698
South Asian (SAS)
AF:
0.0000580
AC:
5
AN:
86256
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53414
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5766
European-Non Finnish (NFE)
AF:
0.0000288
AC:
32
AN:
1111914
Other (OTH)
AF:
0.0000166
AC:
1
AN:
60386
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.443
Heterozygous variant carriers
0
3
5
8
10
13
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00000658
AC:
1
AN:
152062
Hom.:
0
Cov.:
32
AF XY:
0.00
AC XY:
0
AN XY:
74288
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41396
American (AMR)
AF:
0.00
AC:
0
AN:
15254
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5198
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4814
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10584
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.0000147
AC:
1
AN:
68028
Other (OTH)
AF:
0.00
AC:
0
AN:
2090
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.575
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00000945
Hom.:
0
ExAC
AF:
0.0000247
AC:
3
EpiCase
AF:
0.00
EpiControl
AF:
0.000119

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:17
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Pathogenic:5
Mar 31, 2020
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The SDHC c.397C>T, p.Arg133Ter variant (rs764575966) has been reported in multiple patients diagnosed with hereditary paraganglioma syndrome (Bickmann 2014, Zbuk 2007), renal cancer (Ricketts 2012) or gastrointestinal tumors (Miettinen 2013). It is reported as pathogenic in ClinVar (Variation ID: 183753), and observed in the general population with an allele frequency of 0.004% (10/280,416 alleles) in the Genome Aggregation Database. This variant induces an early termination codon and is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. REFERENCES Bickmann J et al. Phenotypic variability and risk of malignancy in SDHC-linked paragangliomas: lessons from three unrelated cases with an identical germline mutation (p.Arg133*). J Clin Endocrinol Metab. 2014; 99(3):E489-96. Miettinen M et al. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol. 2013; 37(2):234-40. Ricketts C et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol. 2012; 188(6):2063-71. Zbuk K et al. Germline mutations in PTEN and SDHC in a woman with epithelial thyroid cancer and carotid paraganglioma. Nat Clin Pract Oncol. 2007; 4(10):608-12. -

Apr 24, 2017
Quest Diagnostics Nichols Institute San Juan Capistrano
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Apr 04, 2022
GeneDx
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Nonsense variant in the C-terminus predicted to result in protein truncation, as the last 37 amino acids are lost, and other loss-of-function variants have been reported downstream in the Human Gene Mutation Database (HGMD); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 22517557, 23282968, 26659639, 19351833, 28973655, 27634942, 24423348, 25525159, 17898811, 23083876, 19454582, 24523625, 24758179, 24102379, 25024072, 27493882, 27700540, 29339836, 26492543, 28819017, 29794110, 26490314, 29386252, 30201732, 31212687, 32272925, 33087929, 30787465, 31447099, 30877234) -

May 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

SDHC: PVS1:Strong, PM2, PP1:Moderate, PS4:Moderate -

May 04, 2018
Genetic Services Laboratory, University of Chicago
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change results in the creation of a premature stop codon at amino acid position 133, p.Arg133*. This pathogenic sequence change is predicted to result in an abnormal transcript, which may be degraded, or may lead to the production of a truncated SDHC protein with potentially abnormal function. This pathogenic sequence change has previously been described in several patient with paragangliomas (OMIM# 605373; Bickmann et. al., 2014; Lefebvre et. al., 2014; Zbuk et. al., 2007). This variant was also found in the germline heterozygous state in several family members that were affected with renal cell carcinoma (Ricketts et. al., 2012). Our interpretation is based on the current understanding of the genetics of SDHC-related disorders. -

Hereditary pheochromocytoma-paraganglioma Pathogenic:4
Apr 01, 2020
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.Arg133X variant in SDHC is believed to be a French Canadian founder variant and been reported in >20 individuals, of mainly French Canadian and French ancestry, with paragangliomas/pheochromocytomas (PGL/PCC: Zbuk 2007, Burnichon 2009, Ricketts 2012, Lefevre 2014, Bickmann 2014, Shuch 2016, Bourdeau 2016). This variant segregated with PGL/PCC in at least 4 affected relatives from 2 families (Bourdeau 2016). In another family (Shuch 2016), the p.Arg133X variant segregated with both renal cell carcinoma (2 affected relatives) and PGL/PCC (1 affected relative). The p.Arg133X variant has also been identified in 0.009% (3/30782) of South Asian chromosomes by gnomAD (http://gnomad.broadinstitute.org; dbSNP rs764575966). Please note that for diseases with clinical variability, reduced penetrance, or recessive inheritance, pathogenic variants may be present at a low frequency in the general population. This nonsense variant leads to a premature termination codon at position 133. This alteration occurs within the terminal 50 bases of the second to last exon and is more likely to escape nonsense mediated decay (NMD) and result in a truncated protein that is missing ~22% of the coding region, with 37 amino acids removed. In summary, this variant meets criteria to be classified as pathogenic for hereditary paraganglioma-pheochromocytoma syndromes in an autosomal dominant manner based on its presence in multiple affected individuals, segregation studies, and low frequency in controls. ACMG/AMP criteria applied: PVS1_Strong, PS4, PM2, PP1_Moderate. -

-
Section on Medical Neuroendocrinolgy, National Institutes of Health
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:research

- -

Feb 05, 2024
All of Us Research Program, National Institutes of Health
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant changes 1 nucleotide in exon 5 of the SDHC gene, creating a premature translation stop signal in the last coding exon. This variant is predicted to escape nonsense-mediated decay and be expressed as a truncated protein. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in over 20 individuals affected with hereditary paranganglioma-pheochromocytoma syndrome (PMID: 24758179, 25024072, 27700540, 28819017), and over 10 individuals with sporadic paranganglioma (PMID: 34750850). This variant is described as a common variant in the French Canadian population (PMID: 27700540), and it has been observed that this variant segregates with disease (PMID: 25024072, 27700540, 28819017). This variant has been identified in 10/280416 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of SDHC function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -

Nov 26, 2024
Color Diagnostics, LLC DBA Color Health
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant changes 1 nucleotide in exon 5 of the SDHC gene, creating a premature translation stop signal in the last coding exon. This variant is predicted to escape nonsense-mediated decay and be expressed as a truncated protein. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in over 20 individuals affected with hereditary paranganglioma-pheochromocytoma syndrome (PMID: 24758179, 25024072, 27700540, 28819017), and over 10 individuals with sporadic paranganglioma (PMID: 34750850). This variant is described as a common variant in the French Canadian population (PMID: 27700540), and it has been observed that this variant segregates with disease (PMID: 25024072, 27700540, 28819017). This variant has been identified in 10/280416 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of SDHC function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -

Pheochromocytoma/paraganglioma syndrome 3 Pathogenic:2
Feb 08, 2024
Myriad Genetics, Inc.
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -

Nov 01, 2016
Center for Human Genetics, Inc, Center for Human Genetics, Inc
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Gastrointestinal stromal tumor;C1847319:Carney-Stratakis syndrome;C1854336:Pheochromocytoma/paraganglioma syndrome 3 Pathogenic:2
Jan 30, 2024
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Aug 19, 2021
Fulgent Genetics, Fulgent Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Gastrointestinal stromal tumor Pathogenic:1
Mar 01, 2024
Baylor Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hereditary cancer-predisposing syndrome Pathogenic:1
Jan 10, 2023
Ambry Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.R133* pathogenic mutation (also known as c.397C>T), located in coding exon 5 of the SDHC gene, results from a C to T substitution at nucleotide position 397. This changes the amino acid from an arginine to a stop codon within coding exon 5. This alteration occurs at the 3' terminus of SDHC gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 37 amino acids of the protein. However, premature stop codons are typically deleterious in nature and the impacted region is critical for protein function. This alteration has been reported in multiple unrelated individuals with paragangliomas (PGLs), gastrointestinal stromal tumors (GIST), renal cell carcinomas, and an adrenocortical carcinoma (Ricketts CJ et al. J. Urol., 2012 Dec;188:2063-71; Miettinen M et al, 2013 Feb;37:234-40; Bickmann JK et al. J. Clin. Endocrinol. Metab., 2014 Mar;99:E489-96; Else T et al. J Clin Endocrinol Metab, 2014 Aug;99:E1482-6; Lefebvre M et al. Curr Oncol, 2014 Feb;21:e8-e17; Else T et al. Eur J Endocrinol, 2017 Nov;177:439-444). In addition, this alteration has been identified in multiple individuals with PGLs of French Canadian descent (Bourdeau I et al. J Clin Endocrinol Metab, 2016 12;101:4710-4718). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -

Gastrointestinal stromal tumor;C1854336:Pheochromocytoma/paraganglioma syndrome 3 Pathogenic:1
Jan 11, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change creates a premature translational stop signal (p.Arg133*) in the SDHC gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 37 amino acid(s) of the SDHC protein. This variant is present in population databases (rs764575966, gnomAD 0.01%). This premature translational stop signal has been observed in individuals with paragangliomas (PGLs) and gastrointestinal stromal tumor (PMID: 17898811, 23083876, 23282968, 24423348, 24523625, 24758179, 27700540). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 183753). Studies have shown that this premature translational stop signal is associated with inconclusive levels of altered splicing (internal data). For these reasons, this variant has been classified as Pathogenic. -

Carney-Stratakis syndrome Pathogenic:1
Aug 17, 2019
Baylor Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
0.46
D
BayesDel_noAF
Pathogenic
0.59
CADD
Pathogenic
41
DANN
Uncertain
1.0
Eigen
Pathogenic
0.78
Eigen_PC
Uncertain
0.65
FATHMM_MKL
Benign
0.75
D
PhyloP100
1.6
Vest4
0.98
GERP RS
5.2
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Mutation Taster
=1/199
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.15
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs764575966; hg19: chr1-161326622; COSMIC: COSV100713709; API